Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest hepatitis C Stories

2013-10-23 16:29:28

200K NYers May Have the Potentially Deadly Disease But Many Don't Know It ALBANY, N.Y., Oct. 23, 2013 /PRNewswire-USNewswire/ -- Gov. Andrew Cuomo has made New York a national leader in protecting baby boomers' health by signing an AARP-backed bill requiring that health care providers offer boomers a screening test for potentially deadly hepatitis C. New York will become the first state in the nation to ensure boomers are offered the important, preventative test. The new Hepatitis...

2013-10-23 08:29:12

Boehringer Ingelheim makes significant investment in groundbreaking hepatitis C program with two leading researchers from the Francis Family Liver Clinic, Toronto Western Hospital University Health Network BURLINGTON, ON, Oct. 23, 2013 /CNW/ - In a move to address a significant unmet need in hepatitis C in Canada, the University Health Network (UHN), together with Boehringer Ingelheim (Canada) Ltd. (BICL), announced today a multi-year partnership that aims to improve care,...

2013-10-21 04:21:09

Inovio is partnering with VGX International, its affiliate, in Korea BLUE BELL, Pa., Oct. 21, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients. Under a 2011 collaborative development agreement, Inovio's affiliate, VGX International Inc. (KSE: 011000), is fully...

2013-10-16 23:25:42

PositiveSingles.com is now offering a 3 day free trial for new singles with Hepatitis C in the next 7days. (PRWEB) October 16, 2013 PositiveSingles.com is doing the unexpected by providing people with Hep C an online platform whereby they can develop friendships and even find love. This international “Hep C Dating” network is experiencing significant growth as more individuals realize its relationship potential for them. According to the CDC, an estimated 150–200 million people...

2013-10-11 08:43:23

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association. The current standard of care for hepatitis C patients includes a combination of peginterferon and ribavirin. "Despite recent advances, the current hepatitis C treatment regimen is burdensome on the patient and prone to adverse events," said Patrick...

2013-10-08 08:29:11

TITUSVILLE, N.J., Oct. 8, 2013 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc. Janssen has acquired all rights to develop and commercialize GSK2336805, including in combination with other drugs. Financial details of the agreement have not been disclosed. Janssen...

2013-10-07 23:18:33

Reportbuyer.com just published a new market research report: PharmaPoint: Hepatitis C Virus - United States Drug Forecast and Market Analysis. London (PRWEB) October 07, 2013 PharmaPoint: Hepatitis C Virus - United States Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus - United States Drug Forecast and Market Analysis”. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute...

2013-10-07 08:25:23

CORK, Ireland, Oct. 7, 2013 /PRNewswire/ -- Data from the Phase 2a COSMOS study (Combination Of SiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS) of the investigational protease inhibitor simeprevir (TMC435) administered once daily with Gilead Sciences Inc.'s investigational nucleotide inhibitor sofosbuvir (GS-7977), with and without ribavirin, in genotype 1 chronic hepatitis C adult patients with compensated liver disease has been accepted as a late-breaking oral presentation...

2013-10-01 12:30:34

RIDGEFIELD, Conn., Oct. 1, 2013 /PRNewswire/ -- New data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical development program have been accepted for presentation at the 64(th) Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting(®), taking place November 1-5 in Washington, D.C. Presentations will include data from several studies evaluating Boehringer Ingelheim's investigational compound, faldaprevir,...

2013-10-01 12:29:43

PHASE III TOP-LINE RESULTS EXPECTED BEGINNING LATER IN 2013 NORTH CHICAGO, Ill., Oct. 1, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that new data from its phase II hepatitis C clinical development program will be presented at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C., November 1-5, 2013. In total, eight abstracts will be presented, four of which include additional analyses from the phase IIb AVIATOR...


Latest hepatitis C Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »